Business · 02/04/2014Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for POTIGA Patent Extension
Summary
The Food and Drug Administration has published a notice determining the regulatory review period for the patent extension of POTIGA, a human drug product, as required by law following an application to the Director of Patents and Trademarks at the Department of Commerce.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →